Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021;144(5):519-527.
doi: 10.1159/000512165. Epub 2021 Feb 25.

Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden

Hareth Nahi  1   2 , Göran Walinder  3   4 , Vishal Patel  5 , Ying Qu  6 , Aaron Levine  6 , Istvan Majer  5 , Lucie Kutikova  5 , Eva Hellqvist Franck  7 , Maria K Svensson  7   8 , Markus Hansson  9   10
Affiliations

Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden

Hareth Nahi et al. Acta Haematol. 2021.

Abstract

Introduction: Treatment-induced peripheral neuropathy (TIPN) is a complication of multiple myeloma (MM) treatment.

Objective: This real-world, retrospective study used electronic medical record (EMR) data from 3 Swedish clinics to assess the occurrence and economic burden of TIPN in patients with MM.

Methods: Eligible patients had an MM diagnosis in the Swedish Cancer Registry between 2006 and 2015 and initiated treatment during that period. Follow-up was until last EMR visit, death, or study end (April 2017). The current analyses included patients receiving bortezomib, lenalidomide, carfilzomib, or thalidomide at any treatment line. To discern healthcare resource utilization (HCRU) and costs associated with TIPN from other causes, patients with TIPN were matched with those without on baseline characteristics, treatment, and line of therapy. All analyses were descriptive.

Results: Overall, 457 patients were included; 102 (22%) experienced TIPN. Patients experiencing TIPN during first-line treatment mostly received bortezomib-based regimens (n = 48/57 [84%]); those with TIPN during second- and third/fourth-line treatment mostly received lenalidomide/thalidomide-based regimens (19/31 [61%], 8/14 [57%], respectively). Patients with TIPN had higher HCRU/costs than those without TIPN (mean differences in hospital outpatient visits: 5.2, p = 0.0031; total costs per patient-year: EUR 17,183, p = 0.0007).

Conclusions: Effective MM treatments associated with a reduced incidence of TIPN could result in decreased healthcare expenditure.

Keywords: Healthcare costs; Healthcare resource utilization; Multiple myeloma; Treatment-induced peripheral neuropathy.

PubMed Disclaimer

Conflict of interest statement

H.N., M.H., and G.W. have no conflicts of interest to declare. Y.Q. and A.L. are employees of IQVIA; IQVIA received research grants from Amgen to conduct this research. V.P., I.M., L.K., E.H.F., and M.K.S. are Amgen employees and stockholders.

Similar articles

See all similar articles

Cited by

References

    1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011 Mar;364((11)):1046–60. - PubMed
    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar;136((5)):E359–86. - PubMed
    1. NORDCAN AotNCR Cancer stat factsheets: Sweden: multiple myeloma. 2019
    1. Smith A, Wisloff F, Samson D. Guidelines on the diagnosis and management of multiple myeloma 2005. Br J Haematol. 2006 Feb;132((4)):410–51. - PubMed
    1. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014 Feb;32((6)):587–600. - PMC - PubMed

MeSH terms